Atea Pharmaceuticals (AVIR) Competitors

Atea Pharmaceuticals (NASDAQ:AVIR) and Nurix Therapeutics (NASDAQ:NRIX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, community ranking, media sentiment, profitability, institutional ownership, risk, dividends and earnings.

Which has more risk and volatility, AVIR or NRIX?

Atea Pharmaceuticals has a beta of 0.18, indicating that its share price is 82% less volatile than the S&P 500. Comparatively, Nurix Therapeutics has a beta of 2.18, indicating that its share price is 118% more volatile than the S&P 500.

Is AVIR or NRIX more profitable?

Atea Pharmaceuticals has a net margin of 0.00% compared to Nurix Therapeutics' net margin of -354.85%. Atea Pharmaceuticals' return on equity of -34.90% beat Nurix Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atea Pharmaceuticals	N/A	-34.90%	-32.38%
Nurix Therapeutics	-354.85%	-53.65%	-38.59%

Which has stronger earnings & valuation, AVIR or NRIX?

Atea Pharmaceuticals has higher earnings, but lower revenue than Nurix Therapeutics. Nurix Therapeutics is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atea Pharmaceuticals	N/A	N/A	-$135.96M	-$2.00	-1.60
Nurix Therapeutics	$54.55M	17.50	-$193.57M	-$2.89	-4.35

Do analysts rate AVIR or NRIX?

Atea Pharmaceuticals presently has a consensus target price of $6.88, suggesting a potential upside of 115.00%. Nurix Therapeutics has a consensus target price of $30.88, suggesting a potential upside of 145.49%. Given Nurix Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Nurix Therapeutics is more favorable than Atea Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atea Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Nurix Therapeutics	0 Sell rating(s)	3 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.83

Does the media favor AVIR or NRIX?

In the previous week, Nurix Therapeutics had 14 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 18 mentions for Nurix Therapeutics and 4 mentions for Atea Pharmaceuticals. Nurix Therapeutics' average media sentiment score of 0.99 beat Atea Pharmaceuticals' score of -0.01 indicating that Nurix Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atea Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nurix Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do insiders and institutionals hold more shares of AVIR or NRIX?

86.7% of Atea Pharmaceuticals shares are held by institutional investors. 17.8% of Atea Pharmaceuticals shares are held by insiders. Comparatively, 7.2% of Nurix Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Does the MarketBeat Community believe in AVIR or NRIX?

Nurix Therapeutics received 62 more outperform votes than Atea Pharmaceuticals when rated by MarketBeat users. Likewise, 77.88% of users gave Nurix Therapeutics an outperform vote while only 48.72% of users gave Atea Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Atea Pharmaceuticals	Outperform Votes 19 48.72%	Underperform Votes 20 51.28%
Nurix Therapeutics	Outperform Votes 81 77.88%	Underperform Votes 23 22.12%

Summary

Nurix Therapeutics beats Atea Pharmaceuticals on 9 of the 17 factors compared between the two stocks.